CYDY Stock Price Estimate
There has been a lot of
CYDY Stock Price Estimate
There has been a lot of discussion about what CYDY can reach for a stock price so I started to do some digging into a few of the numbers. Here is my estimate of the POTENTIAL stock price if everything goes as planned for the next 2-5 years.
I figure this a good start and this is what CYDY could capture of those dollars with approvals. I tried to be very conservative and would welcome anyone’s thoughts on how they would change the numbers.
Maybe it’s production restrictions, % of market to capture, total $ of the market. Please critique and respond accordingly.
COVID $10 billion/year CYDY 20% of Market for M/M & S/C
$2 billion
NASH $22 billion/year CYDY 75% of market— At present, there is no FDA approved drug to treat NASH.
$16.5 billion
Long Haulers $1 billion/year Total WAG on this as no one really knows as it is so new
CYDY 50% of market
$.5 billion
Cancer $179 billion/year
CYDY—another WAG, let’s go with 3%
$5.4 billion
HIV $30+ billion/year
CYDY 20% of Market
$6 billion
Total Sales $38.9 billion sales potential per year in 3-5 years.
For simplicity sake, I will only use a 1:1 ratio of Price/Sales. Just an easy way and safer way to calculate the stock price. Every industry is different and growth rate can influence this ratio/number to go up or down.
CytoDyn Shares Outstanding:598.13M for Dec. 31, 2020
$38 Billion /598 million shares = $65/share
Let’s take dilution/competition/etc and factor those to 50%
$65 * 50% $32.50/share
I can’t even begin to calculate all 50+ indications on Ohm’s list. If someone else wants to take a run at it, go for it and let us all know. A small example is Rheumatoid Arthritis ALONE—this is a $25-30 billion per year for a market size. C
I guess what this says to me is that $50 is VERY obtainable, $100 is on the near horizon and who knows from there.
NJ
9
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A New Wave of AI-Powered Solutions Hot off the press, Gooru AI's recent shindig in the heart of Dallas aimed to showcase something they call 'Digital Goorus.' Now that might sound like a newage tech gimmick but peel back the layers and you find an ambitious attempt to let folks spread their smarts without having to be everywhere all at once. Imagine being able to crack...
Continue Reading
A New Chapter for a Seasoned Entrepreneur There's a certain irony in a seasoned business vet stepping into a new role at his own daughter's company, and that's exactly what's unfolding with the Bailors. Huntsville's own BAILOR isn't just another growth strategy company; it's the embodiment of a father-daughter dream team. After years as the ordinary head honcho, Bob...
Continue Reading
Class Action Stirred by BCD Travel Data Breach Here's the scoop, folks: Edelson Lechtzin LLP, a heavyweight in the world of class action law firms, is sniffing around BCD Travel Services B.V. over a juicy data breach that left about 700,000 traveler records flapping in the wind. Grab your coffee—this one's got all the trimmings of a modern-day digital fiasco. The Breach...
Continue Reading
Sentral's Strategic Leap into New Markets Ever heard of a company spreading its wings like wildfire? That’s Sentral for you, crashing into Fort Lauderdale and pushing deeper roots in San Diego. We’re not talking minor plays here—these two fresh additions make Sentral a resident-giant stretched across 22 markets. Seems like they’re on a mission to ink their mark...
Continue Reading
Pressure Mounts on Duolingo Amid Legal Turmoil Well, here's a riddle solved with a lawsuit: when an app's growth hits the brakes, the lawyers seem to get moving fast. It seems like Duolingo, Inc. (NasdaqGS: DUOL) is learning a harsh lesson—not exactly in Spanish or French, but in the courtroom. They've been slapped with a securities class action, and it ain't looking...
Continue Reading
End of an Era in Periodontology For those of us who have a stake in the world of dental technology, today hangs heavy. We talk about innovators, pioneers, and game-changers all the time, but Dr. Raymond A. Yukna wasn't just another name on that list - he was the list. The guy practically wrote the book on modern periodontal therapy. With his passing, we're not just saying...
Continue Reading
Rethinking the Anti-TIGIT Game with HCB303 There's a fresh breeze blowing in the realm of immunotherapy, and it comes courtesy of HanchorBio's innovative trispecific approach. Now, for those of us who've been unimpressed by the underwhelming returns from anti-TIGIT trials, this new development might just stir the pot. HanchorBio's got the green light not only from the...
Continue Reading
A New Dimension to Halloween's Visuals You ever notice how some TVs just can’t do justice to a Halloween flick? It’s all about the details—those rich, spooky colors and the perfectly balanced light and shadow. The nuance in the shadowy folds of a cape or the eerie glow of a lantern is crucial. Hisense's RGB MiniLED technology is showing up just in time to rescue...
Continue Reading
Everest Group's Legal Quagmire: A Rocky Road Ahead Riding high has its pitfalls. I mean just take a gander at Everest Group, Ltd. (NYSE: EG). The suits and stocks got their knickers in a twist when the company's missteps saw them landing smack dab in the middle of a shareholder class-action lawsuit. It's gloomy days, my friend, especially if you're carrying a portfolio...
Continue Reading
Another Market Flash: Gildan Enters Rough Waters New Orleans has put a spotlight on Gildan Activewear, and not in a flattering way. We're talking about that precarious position corporations sometimes find themselves in when their dirty laundry gets aired out for the public to scrutinize. ClaimsFiler, the service urging shareholders to come forward, reminds folks that the...
Continue Reading
Top 5 Most Recently Viewed Articles
Apollo Funds Set to Acquire European Data Center Operations LONDON and NEW YORK — Apollo (NYSE: APO) has officially announced a landmark deal in the realm of digital infrastructure. Their managed infrastructure funds will acquire the European colocation business from STACK Infrastructure, marking a strategic growth initiative. This acquisition involves multiple data...
Continue Reading
TransCode Therapeutics Details Latest Stock Offering TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a pioneering RNA oncology company dedicated to advancing cancer treatment through RNA therapeutics, has recently announced the terms of its latest registered direct offering. This significant move involves the sale of 10,250,000 shares of common stock alongside warrants for...
Continue Reading
First Federal Bank's Expansion Plans First Federal Bank has taken a significant step in its growth strategy by opening a new branch in Jacksonville. This marks the 26th full-service banking center for the institution, further solidifying its presence in the region. With existing branches in areas like Macclenny and Fernandina, this new location aims to cater to the...
Continue Reading
Zuckerman Investment Group Recognized as a Leading Workplace Zuckerman Investment Group, a renowned family-owned wealth management firm, has proudly announced that it has earned a prestigious spot on the list of the Best Places to Work for Financial Advisors, a recognition awarded by InvestmentNews for 2025. This accolade marks the fourth consecutive year that the firm...
Continue Reading
Enhancing Industrial Automation with AI In the ever-evolving landscape of industrial automation, Telit Cinterion is at the forefront, introducing cutting-edge solutions that significantly enhance operational efficiency. Recently, the company announced an integration with NVIDIA TAO 6.0 that empowers its deviceWISE® AI Visual Inspection platform. This powerful combination...
Continue Reading